首页>
外文期刊>The Korean Journal of Internal Medicine
>Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity
【24h】
Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity
The objective of this study was to compare changes in the simplified disease activity index (SDAI) between biologic (b) and conventional (c) disease-modifying antirheumatic drugs (DMARD) users with seropositive rheumatoid arthritis (RA) in daily clinical practice. This was a nationwide multicenter observational study. Patients who had three or more active joint counts and abnormal inf lammatory marker in blood test were enrolled. The selection of DMARDs was determined by the attending rheumatologist. Clinical parameters, laboratory findings, and Health Assessment Questionnaire (HAQ) scores were obtained at baseline and at 6 and 12 months. Serial SDAI changes and clinical remission rate at 6 and 12 months were assessed. A total of 850 patients participated in this study. The mean baseline SDAI score in bDMARD group was higher than that in cDMARD group (32.08 ± 12.98 vs 25.69 ± 10.97, p 0.0001). Mean change of SDAI at 12 months was -19.0 in the bDMARD group and -12.6 in the cDMARD group (p 0.0001). Clinical remission rates at 12 months in bDMARD and cDMARD groups were 15.4% and 14.6%, respectively. Patient global assessment and HAQ at 12 months were also significantly improved in both groups. Multivariate logistic regression showed that baseline HAQ score was the most notable factor associated with remission. There was a significant reduction in SDAI within 12 months after receiving DMARDs in Korean seropositive RA patients irrespective of bDMARD or cDMARD use in real-world practice. Clinical remission was achieved in those with lower baseline HAQ scores.
展开▼
机译：本研究的目的是在日常临床实践中与血清阳性类风湿性关节炎（RA）进行生物学（B）和常规（C）疾病修饰的抗呼吁药物（DMARD）用户之间的简化疾病活动指数（SDAI）的变化。这是一个全国范围的多中心观察研究。注册了在血液试验中具有三个或更多活性关节计数和异常患有血液禁止标志物的患者。 DMARD的选择是由参加风湿病学确定的。临床参数，实验室调查结果和健康评估问卷（HAQ）分数在基线和6月6日和6个月内获得。评估序列SDAI的变化和临床缓解率为6和12个月。共有850名患者参加了这项研究。 BDMARD组的平均基线SDAI评分高于CDMARD组（32.08±12.98 Vs 25.69±10.97，P <0.0001）。 12个月的SDAI的平均变化为-19.0在BDMARD组和CDMARD组中的-12.6（P <0.0001）。 BDMARD和CDMARD组12个月的临床缓解率分别为15.4％和14.6％。两组患者在12个月内的患者全球评估和HAQ也显着改善。多变量逻辑回归显示，基线HAQ得分是与缓解相关的最值得注意的因素。在韩国血清阳性RA患者接受DMARD后，SDAI在韩国血清阳性RA患者的患者中有显着减少，而不管是在现实世界实践中的BDMARD或CDMARD使用。在较低的基线HAQ分数的那些中取得了临床缓解。
展开▼
